Novo Nordisk(US:NVO) Hua Er Jie Jian Wen·2025-07-31 08:40Group 1 - Novo Nordisk has lowered its 2025 fiscal year performance guidance, indicating a potential conservative management approach or a substantial deterioration in business prospects [1][4] - Deutsche Bank's report suggests that the new management's growth targets are very conservative, with the current market pricing Novo Nordisk as a mature pharmaceutical stock [1][4] - The revised guidance for 2025 sales growth is now set at 8-14% and EBIT growth at 10-16%, which is close to Deutsche Bank's previous expectations [4] Group 2 - The competition from compounded drugs continues to affect Novo Nordisk, with approximately 1 million patients in the U.S. still using compounded medications [2] - Despite an increase in 503A supply to offset the decline in 503B, the overall competitive landscape has not improved [2] - Analysts believe that Novo Nordisk should expand its market for semaglutide-based drugs in the second half of the year, but failure to do so may indicate issues with the total addressable market (TAM) theory [2] Group 3 - The new CEO of Novo Nordisk prioritizes innovation investment and business execution, with cash prescription business share rising from 4% to 12% since the beginning of the year [3] - The company confirmed that out of 100 million obese individuals, 55 million have employer-sponsored insurance for Wegovy, with compounded drugs accounting for 30% of the market [3] - Wegovy's prescription volume is approximately 275,000, with new prescription share exceeding 40% [3]